Weill Cornell Medicine researchers have pinpointed a crucial brain circuit that explains how transcranial magnetic stimulation (TMS) alleviates depression—a finding that could transform treatment for one of the world's most common mental health conditions. The discovery centers on a neural pathway connecting the prefrontal cortex, near the front of the brain, to the insular cortex, a deeper region previously overlooked in TMS research. The work, published in Cell, opens new possibilities for delivering therapy more effectively to millions of people who suffer from depression.
Depression affects tens of millions of Americans annually, according to the National Institute of Mental Health, and its prevalence has been climbing for decades. While selective serotonin reuptake inhibitors remain the most common treatment, they often take weeks to work and frequently trigger side effects. TMS offers a more targeted alternative with minimal side effects, especially for patients who don't respond to medication. One newer TMS protocol called accelerated intermittent theta-burst stimulation (aiTBS) has shown striking promise, reducing or abolishing depression symptoms in many patients after just a few days of treatment—but exactly how it works has remained a mystery.
Dr. Conor Liston, the Robert Michels Professor of Psychiatry at Weill Cornell Medicine, led the team in developing an optogenetic mouse model to crack the code. By using light pulses to stimulate specific neurons with the same rhythms used in aiTBS, researchers could observe precisely which brain regions and connections drive the antidepressant effect. They found that stimulating the prefrontal cortex reversed stress-induced, depression-like behaviors in mice—and crucially, this effect depended entirely on an indirect connection to the insular cortex.
When the team traced the neurons' connections and examined them more closely, they discovered structural changes that occur in response to stimulation, including denser growths of connections between brain cells. But none of this mattered without the pathway to the insular cortex. That connection proved essential. "The insula hasn't been covered much in TMS research, in part because it is too deep in the brain to reach with ordinary TMS protocols," Dr. Liston explained, "but it is one of the most consistently altered brain regions in studies of patients with depression." The insular cortex processes bodily sensations—hunger, pain—and integrates them with emotion-related signals, making it a crucial hub for mood regulation.
To ensure their mouse findings could actually apply to people, the researchers didn't stop at animal models. They used functional magnetic resonance imaging and electroencephalography to map brain connections and measure neural responses in consented TMS patients. This translation from mice to humans validates the circuit's importance and suggests new avenues for refining therapy.
The implications are substantial. Because TMS delivery involves numerous variables—session duration, pulse rhythm, intervals between sessions, and the specific brain target—systematic testing has been nearly impossible in humans. Understanding that the prefrontal-to-insular pathway is central to the antidepressant effect gives clinicians a concrete target and researchers a measurable endpoint for optimization. "We're excited about this work because it advances our understanding of the antidepressant effects of TMS, and points to more effective ways of delivering this therapy," Dr. Liston said.
For millions struggling with depression, this clarity matters profoundly. It means treatment could become faster, more reliable, and better tailored to individual brain architecture.